Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • AQX-1125: Additional Phase II data

    Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP), Vancouver, B.C. Product: AQX-1125 Business: Genitourinary Molecular target: SH2-containing inositol 5-phosphatase (SHIP) Description: SH2-containing inositol 5-phosphatase (…

    Published on 8/24/2015
  • ATB-346: Phase I data

    Antibe Therapeutics Inc. (TSX-V:ATE), Hamilton, Ontario Product: ATB-346 Business: Neurology Molecular target: Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2) Description: Hydrogen sulfide-releasing derivative of …

    Published on 8/24/2015
  • Atezolizumab: Phase II data

    Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Atezolizumab (Anti-PDL1) (MPDL3280A, RG7446) Business: Cancer Molecular target: Programmed cell death 1 ligand 1 (PD-…

    Published on 8/24/2015
  • Autologous T cell therapy against CD19: Phase I data

    Kite Pharma Inc. (NASDAQ:KITE), Los Angeles, Calif. Product: Autologous T cell therapy against CD19 (KTE-C19) Business: Cancer Molecular target: CD19 Description: Autologous T cells genetically modified to express a …

    Published on 8/24/2015
  • AVN-211: Phase IIb data

    AllaChem LLC, Hallandale Beach, Fla. Avineuro Pharmaceuticals Inc., San Diego, Calif. Product: AVN-211 Business: Neurology Molecular target: Serotonin (5-HT6) receptor Description: Small molecule serotonin (5-HT6) …

    Published on 8/24/2015
  • Benzhydrocodone/acetaminophen: Clinical trial data

    KemPharm Inc. (NASDAQ:KMPH), Coralville, Iowa Product: Benzhydrocodone/acetaminophen (KP201/APAP) (KP201) Business: Neurology Molecular target: NA Description: Abuse-deterrent formulation of benzhydrocodone, a …

    Published on 8/24/2015
  • CureXcell: Phase III data

    Macrocure Ltd. (NASDAQ:MCUR), Petah Tikva, Israel Product: CureXcell Business: Dermatology Molecular target: NA Description: Suspension containing activated allogeneic white blood cells isolated from the peripheral …

    Published on 8/24/2015
  • Gantenerumab: Phase III data

    MorphoSys AG (Xetra:MOR; Pink:MPSYF), Martinsried, Germany Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Gantenerumab (R1450, RG1450) Business: …

    Published on 8/24/2015
  • ITCA 650: Phase III data

    Intarcia Therapeutics Inc., Boston, Mass. Servier, Neuilly-sur-Seine, France Product: ITCA 650 Business: Endocrine/Metabolic Molecular target: Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R) Description: Continuous …

    Published on 8/24/2015
  • Jardiance empagliflozin: Phase III data

    Boehringer Ingelheim GmbH, Ingelheim, Germany Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Jardiance empagliflozin (BI-10773) Business: Endocrine/Metabolic Molecular target: Sodium-glucose cotransporter 2 (…

    Published on 8/24/2015
  • OMS721: Phase II data

    Omeros Corp. (NASDAQ:OMER), Seattle, Wash. Product: OMS721 Business: Hematology Molecular target: Mannan-binding lectin-associated serine protease-2 (MASP-2) Description: Human mAb against mannan-binding lectin-…

    Published on 8/24/2015
  • Roxadustat: Phase IIa data

    FibroGen Inc. (NASDAQ:FGEN), San Francisco, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Roxadustat (FG-4592, ASP1517) Business: Hematology Molecular …

    Published on 8/24/2015
  • Secnidazole: Additional Phase II data

    Symbiomix Therapeutics LLC, Newark, N.J. Product: Secnidazole (SYM-1219) Business: Infectious Molecular target: NA Description: Granule formulation of a next-generation, 5-nitroimidazole antibiotic Indication: Treat …

    Published on 8/24/2015
  • Sinogliatin: Phase Ic data

    Hua Medicine Ltd., Shanghai, China Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Sinogliatin (HMS5552, RO5305552) Business: Endocrine/Metabolic Molecular target: Glucokinase (GCK) (GK) Description: Small …

    Published on 8/24/2015
  • SMT C1100: Phase Ib data

    Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT), Abingdon, U.K. Product: SMT C1100 (formerly BMN 195) Business: Musculoskeletal Molecular target: Utrophin (UTRN) Description: Small molecule utrophin (UTRN) modulator …

    Published on 8/24/2015
  • Stivarga regorafenib: Phase III data

    Bayer AG (Xetra:BAYN), Leverkusen, Germany Product: Stivarga regorafenib (fluoro-sorafenib) (BAY 73-4506) Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1); …

    Published on 8/24/2015
  • Stivarga regorafenib: Phase IIIb data

    Bayer AG (Xetra:BAYN), Leverkusen, Germany Product: Stivarga regorafenib (fluoro-sorafenib) (BAY 73-4506) Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1); …

    Published on 8/24/2015
  • Thioureidobutyronitrile: Interim Phase I data

    Cellceutix Corp. (OTCQB:CTIX), Beverly, Mass. Product: Thioureidobutyronitrile (Kevetrin) Business: Cancer Molecular target: Protein kinase B (AKT) (AKT1) (PKB) (PKBA); Leukotriene B4 (LTB4) Description: Small molecule …

    Published on 8/24/2015
  • Trumenba: Phase III data

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Trumenba (recombinant LP2086) (rLP2086, PF-5212366, PF-05212366) Business: Infectious Molecular target: NA Description: Bivalent meningococcal B vaccine targeting LP2086 (…

    Published on 8/24/2015
  • Trumenba: Phase III data

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Trumenba (recombinant LP2086) (rLP2086, PF-5212366, PF-05212366) Business: Infectious Molecular target: NA Description: Bivalent meningococcal B vaccine targeting LP2086 (…

    Published on 8/24/2015
  • V158866: Development discontinued

    Vernalis plc (LSE:VER), Winnersh, U.K. Product: V158866 Business: Neurology Molecular target: Fatty acid amide hydrolase (FAAH) Description: Small molecule inhibitor of fatty acid amide hydrolase (FAAH) Indication: …

    Published on 8/24/2015
  • Vonapanitase: Phase I data

    Proteon Therapeutics Inc. (NASDAQ:PRTO), Waltham, Mass. Product: Vonapanitase (formerly PRT-201) Business: Cardiovascular Molecular target: Elastase Description: Recombinant human elastase Indication: Treat symptomatic …

    Published on 8/24/2015
  • Vyvanse: Phase III data

    Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Product: Vyvanse (Elvanse, Tyvense, Venvanse) lisdexamfetamine dimesylate (S-877489) Business: Neurology Molecular target: Not available Description: Prodrug of …

    Published on 8/24/2015
  • Acarovac Plus: Clinical trial data

    Allergy Therapeutics plc (LSE:AGY), London, U.K. Product: Acarovac Plus Business: Inflammation Molecular target: NA Description: Tyrosine-adsorbed, modified-allergen product containing extracts of selectively purified …

    Published on 8/17/2015
  • AYX1: Phase IIb data

    Adynxx Inc., San Francisco, Calif. Product: AYX1 Business: Neurology Molecular target: Early growth response 1 (EGR1) Description: Small synthetic dsDNA inhibitor of early growth response 1 (EGR1) Indication: Reduce …

    Published on 8/17/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993